These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

425 related items for PubMed ID: 12100776

  • 21. The COX-2 specific inhibitor Valdecoxib versus tramadol in acute ankle sprain: a multicenter randomized, controlled trial.
    Ekman EF, Ruoff G, Kuehl K, Ralph L, Hormbrey P, Fiechtner J, Berger MF.
    Am J Sports Med; 2006 Jun; 34(6):945-55. PubMed ID: 16476920
    [Abstract] [Full Text] [Related]

  • 22. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
    Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, Andrade-Ortega L, Wallemark C, Agrawal NM, Eisen GM, Stenson WF, Triadafilopoulos G, SUCCESS-I Investigators.
    Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472
    [Abstract] [Full Text] [Related]

  • 23. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.
    Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM.
    Eur J Gastroenterol Hepatol; 2002 Oct; 14(10):1101-11. PubMed ID: 12362101
    [Abstract] [Full Text] [Related]

  • 24. Valdecoxib for treatment of a single, acute, moderate to severe migraine headache.
    Kudrow D, Thomas HM, Ruoff G, Ishkanian G, Sands G, Le VH, Brown MT.
    Headache; 2005 Oct; 45(9):1151-62. PubMed ID: 16178945
    [Abstract] [Full Text] [Related]

  • 25. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis.
    Kriegel W, Korff KJ, Ehrlich JC, Lehnhardt K, Macciocchi A, Moresino C, Pawlowski C.
    Int J Clin Pract; 2001 Oct; 55(8):510-4. PubMed ID: 11695069
    [Abstract] [Full Text] [Related]

  • 26. Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies.
    Daniels SE, Desjardins PJ, Bird SR, Smugar SS, Tershakovec AM.
    Clin Ther; 2006 Jul; 28(7):1022-34. PubMed ID: 16990080
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee.
    Babul N, Noveck R, Chipman H, Roth SH, Gana T, Albert K.
    J Pain Symptom Manage; 2004 Jul; 28(1):59-71. PubMed ID: 15223085
    [Abstract] [Full Text] [Related]

  • 28. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee.
    Schnitzer TJ, Kivitz AJ, Lipetz RS, Sanders N, Hee A.
    Arthritis Rheum; 2005 Dec 15; 53(6):827-37. PubMed ID: 16342089
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis.
    Dahlberg LE, Holme I, Høye K, Ringertz B.
    Scand J Rheumatol; 2009 Dec 15; 38(2):133-43. PubMed ID: 19165648
    [Abstract] [Full Text] [Related]

  • 32. Valdecoxib for treatment of primary dysmenorrhea. A randomized, double-blind comparison with placebo and naproxen.
    Daniels SE, Torri S, Desjardins PJ.
    J Gen Intern Med; 2005 Jan 15; 20(1):62-7. PubMed ID: 15693930
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial.
    Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, Hubbard RC, Isakson PC, Verburg KM, Geis GS.
    Mayo Clin Proc; 1999 Nov 15; 74(11):1095-105. PubMed ID: 10560596
    [Abstract] [Full Text] [Related]

  • 35. Tramadol allows reduction of naproxen dose among patients with naproxen-responsive osteoarthritis pain: a randomized, double-blind, placebo-controlled study.
    Schnitzer TJ, Kamin M, Olson WH.
    Arthritis Rheum; 1999 Jul 15; 42(7):1370-7. PubMed ID: 10403264
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
    Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Seidenberg BC, Bellamy N.
    J Rheumatol; 2000 Nov 15; 27(11):2635-41. PubMed ID: 11093446
    [Abstract] [Full Text] [Related]

  • 38. Efficacy, safety, and effects on blood pressure of naproxcinod 750 mg twice daily compared with placebo and naproxen 500 mg twice daily in patients with osteoarthritis of the hip: a randomized, double-blind, parallel-group, multicenter study.
    Baerwald C, Verdecchia P, Duquesroix B, Frayssinet H, Ferreira T.
    Arthritis Rheum; 2010 Dec 15; 62(12):3635-44. PubMed ID: 20722026
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial.
    DeLemos BP, Xiang J, Benson C, Gana TJ, Pascual ML, Rosanna R, Fleming B.
    Am J Ther; 2011 May 15; 18(3):216-26. PubMed ID: 20215961
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.